Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: A cluster randomised trial

The Lancet

Volumn 384, Issue 9938, 2014, Pages 153-163

  Weaver, Tim ^a   Metrebian, Nicola ^b   Hellier, Jennifer ^b   Pilling, Stephen ^c   Charles, Vikki ^b   Little, Nicholas ^c   Poovendran, Dilkushi ^a   Mitcheson, Luke ^d   Ryan, Frank ^e   Bowden Jones, Owen ^f   Dunn, John ^e   Glasper, Anthony ^g   Finch, Emily ^d   Strang, John ^b,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

^f CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g Sussex Partnership Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ARTICLE; CAUSE OF DEATH; CONTINGENCY MANAGEMENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG USE; ETHNICITY; FEMALE; FOLLOW UP; HEALTH CARE MANAGEMENT; HEALTH SERVICE; HEART ARREST; HEPATITIS B; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH SERVICE; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; UNITED KINGDOM; VACCINATION; BEHAVIOR CHANGE; PRAISE; REINFORCEMENT; REWARD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEROIN DEPENDENCE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTIVATION; OPIATE SUBSTITUTION TREATMENT; VACCINATION; YOUNG ADULT;

EID: 84904177729     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60196-3     Document Type: Article

References (36)

1. WHO. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003.
2. Strang J, Babor T, Caulkins J, Fischer B, Foxcroft D, Humphreys K. Drug policy and the public good: evidence for effective interventions. Lancet 2012; 379: 71-83.
3. Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255-64.
4. Kazdin AE. Behaviour modification in applied settings. Belmont, CA: Wadsworth Publishing, 2000.
5. Higgins ST, Silverman K, Hall SH, eds. Contingency management in substance abuse treatment. New York: Guilford Press, 2008.
6. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-Analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006; 101: 192-203.
7. NICE. Drug misuse: psychosocial interventions. Clinical guideline 51. London: National Institute for Health and Care Excellence, 2007.
8. Pilling S, Strang J, Gerada C, on behalf of the Guideline Development Groups. Psychosocial interventions and opioid detoxification for drug misuse: summary of NICE guidance. BMJ 2007; 335: 203-05.
9. Seal KH, Kral AH, Lorvick J, McNees A, Gee L, Edlin BR. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003; 71: 127-31.
10. Stitzer ML, Polk T, Bowles S, Kosten T. Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend 2010; 107: 76-79.
11. Petry NM. Contingency management treatments. Br J Psychiatry 2006; 189: 97-98.
12. WHO. Prevention & control of viral hepatitis infection: framework for global action. Geneva: World Health Organization, 2012.
13. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
14. WHO. Policy brief: guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World Health Organization, 2012.
15. Judd A, Hickman M, Hope VD, et al. Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? J Viral Hepat 2007; 14: 584-91.
16. Department of Health. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health, 2007.
17. Hope VD, Ncube F, Hickman M, Judd A, Parry JV. Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements? J Viral Hepat 2007; 14: 653-60.
18. Lamagni TL, Hope VD, Davison KL, Parry JV, Gill ON. Failure to vaccinate current injecting drug users against hepatitis B in England and Wales. Commun Dis Public Health 2001; 4: 71-72.
19. Brim N, Zaller N, Taylor LE, Feller E. Twinrix vaccination schedules among injecting drug users. Expert Opin Biol Ther 2007; 7: 379-89.
20. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992; 87: 733-42.
21. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993; 88: 791-804.
22. EuroQol Group. EuroQol-A new facility for the measurement ofhealth-related quality of life. Health Policy 1990; 16: 199-208.
23. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
24. Campbell MK, Mollison J, Steen N, Grimshaw JM, Eccles M. Analysis of cluster randomized trials in primary care: a practical approach. Fam Pract 2000; 17: 192-96.
25. Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. Int J Epidemiol 2006; 35: 1292-300
26. Norton EC, Bieler GS, Ennett ST, Zarkin GA. Analysis of prevention program effectiveness with clustered data using generalized estimating equations. J Consult Clin Psychol 1996; 64: 919-26.
27. Marsden J, Eastwood B, Bradbury C, et al, and the National Drug Treatment Monitoring System Outcomes Study Group. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet 2009; 374: 1262-70.
28. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-Analysis. Addiction 2006; 101: 1546-60.
29. Malotte CK, Hollingshead JR, Larro M. Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med 2001; 20: 103-07.
30. Chaisson RE, Barnes GL, Hackman J, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med 2001; 110: 610-15.
31. Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend 2002; 66: 283-93.
32. Sorensen JL, Haug NA, Delucchi KL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend 2007; 88: 54-63.
33. Trubatch BN, Fisher DG, Cagle HH, Fenaughty AM. Vaccination strategies for targeted and difficult-to-Access groups. Am J Public Health 2000; 90: 447.
34. Des Jarlais DC, Fisher DG, Newman JC, et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health 2001; 91: 1791-92.
35. Topp L, Day CA, Wand H, et al, and the Hepatitis Acceptability and Vaccine Incentives Trial (HAVIT) Study Group. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Prev Med 2013; 57: 297-303.
36. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-65.